Back to all studies
CompletedNCT01527305

Paliperidone Palmitate for schizophrenia

This study is completed in China, in Malaysia, in South Korea, .... It is testing paliperidone Palmitate for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT01527305. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

Check the official registry

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

China · 6 sites
  • Huzhou
    Huzhou
    Site status: Not listed — confirm with the team
  • Shanghai
    Shanghai
    Site status: Not listed — confirm with the team
  • Shantou
    Shantou
    Site status: Not listed — confirm with the team
  • Suzhou
    Suzhou
    Site status: Not listed — confirm with the team
  • Wenzhou
    Wenzhou
    Site status: Not listed — confirm with the team
  • Wuxi
    Wuxi
    Site status: Not listed — confirm with the team
Malaysia · 3 sites
  • Johor Bahru
    Johor Bahru
    Site status: Not listed — confirm with the team
  • Kuala Lumpur
    Kuala Lumpur
    Site status: Not listed — confirm with the team
  • Tanjong Rambutan
    Tanjong Rambutan
    Site status: Not listed — confirm with the team
South Korea · 7 sites
  • Busan
    Busan
    Site status: Not listed — confirm with the team
  • Goyang
    Goyang
    Site status: Not listed — confirm with the team
  • Gyeonggi-do
    Gyeonggi-do
    Site status: Not listed — confirm with the team
  • Jeonju
    Jeonju
    Site status: Not listed — confirm with the team
  • Kyounggi
    Kyounggi
    Site status: Not listed — confirm with the team
  • Seoul
    Seoul
    Site status: Not listed — confirm with the team
  • Suwon
    Suwon
    Site status: Not listed — confirm with the team
Taiwan · 5 sites
  • Douliou City, Yunlin County
    Douliou City, Yunlin County
    Site status: Not listed — confirm with the team
  • Kaohsiung City
    Kaohsiung City
    Site status: Not listed — confirm with the team
  • New Taipei City
    New Taipei City
    Site status: Not listed — confirm with the team
  • Taichung
    Taichung
    Site status: Not listed — confirm with the team
  • Taipei
    Taipei
    Site status: Not listed — confirm with the team
In plain English

Key information made simple

What is this study testing?

This study is testing whether Paliperidone Palmitate may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Paliperidone Palmitate, attend study visits with the research team. The registry lists locations in China, in Malaysia, and in South Korea.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: June 22, 2012
Recruitment status
Completed
Enrollment listed in the registry
212
Sponsor
Janssen Research & Development, LLC
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
China, Malaysia, South Korea, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01527305
Official title
An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT01527305. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Paliperidone palmitate. Phase 4 studies usually happen after treatment approval, to monitor real-world use.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Janssen Research & Development, LLC, which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me